Cerebrolysin: reported timelines in the literature

Cerebrolysin is a multimodal neuropeptide preparation of porcine brain-derived peptides and free amino acids, also referred to in the literature as a neurotrophic peptide preparation or neuropeptide preparation. The evidence block supplied for this page does not give a sequence, molecular formula, or molecular weight for the preparation, so none is stated here. The work summarised below centres on neurotrophic and neuroplasticity-associated signalling, with the mechanistic in vitro work focusing on cerebral endothelial cell permeability and tight-junction-related protein cargo in released exosomes [4].

Reported timelines in the literature are heterogeneous by design. They come from a randomised trial protocol in extended-window thrombectomy [1], single-patient case reports [2][3][9], an in vitro permeability assay [4], conference abstracts on adjunctive rehabilitation [6][7][8], and a set of retraction notices [5][10][11][12]. Where a finding is animal-only or in vitro, that is stated plainly in the relevant section. No human dose, schedule, or outcome is given or implied anywhere on this page.

Research Studies

Cerebrolysin and post-thrombectomy recovery in extended-window stroke

A multicentre randomised clinical trial is evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, reduces brain tissue injury and supports recovery [1]. The rationale given is that endovascular thrombectomy can benefit selected patients treated 6 to 24 hours after onset, but some patients remain disabled even when the blocked artery is reopened, with ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier proposed as contributors to incomplete recovery [1]. The trial is registered and ongoing; the evidence block does not report results, effect sizes, or a completion timeline, so no timeline can be quoted from it.

Cerebrolysin and 12-month functional outcomes after endovascular thrombectomy

A conference abstract reports 12-month functional outcomes in a propensity-matched cohort of stroke patients who received Cerebrolysin after endovascular thrombectomy [8]. The abstract is indexed with a licence permitting non-commercial reuse, and the evidence block supplies no numerical results. The 12-month horizon is the longest post-thrombectomy follow-up window named anywhere in the supplied evidence.

Cerebrolysin and basilar artery occlusion after mechanical thrombectomy

A case report describes a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction grade 3), with adjunctive Cerebrolysin administered subsequently [2]. Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) by a later timepoint [2]. This is a single-patient observation in a posterior-circulation stroke population and does not establish a timeline for any other patient or setting.

Cerebrolysin and Wernicke's aphasia with speech-language therapy

A case report describes a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischemic stroke and, despite timely thrombolysis and mechanical thrombectomy, experienced significant neurological deficits [3]. Early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was administered [3]. The 10-day course is the only named administration window in this report; the evidence block does not give the follow-up interval at which outcomes were assessed.

Cerebrolysin and very early short-course administration after tenecteplase and thrombectomy

A case report describes an 88-year-old woman and reports that, despite high recanalisation rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, with Cerebrolysin proposed as a multimodal neuropeptide preparation that may attenuate ischemia-reperfusion injury and support early neurorehabilitation [9]. This item is marked reference-only and is cited here as supporting context rather than as the subject of a section. The evidence block does not supply the administration window or follow-up interval for this case.

Cerebrolysin and cerebral endothelial cell permeability in vitro

In an in vitro endothelial permeability assay, exosomes released by Cerebrolysin-treated cerebral endothelial cells were tested for their effect on dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between exosomes from Cerebrolysin-treated cells and exosomes from untreated cells, with the treated-cell exosomes highly enriched in metabolic and tight junction related proteins [4]. The treated-cell exosomes had a superior effect compared to untreated-cell exosomes on restoring cerebral endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This is an in vitro finding in cultured endothelial cells and does not describe a clinical timeline.

Cerebrolysin combined with speech therapy in nonfluent aphasia

A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischemic stroke [6]. The abstract is indexed under a non-commercial licence and the evidence block supplies no pooled effect estimate, no number of included studies, and no follow-up window.

Cerebrolysin as an add-on to virtual reality neurorehabilitation in acute stroke

A conference abstract reports on virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. As with the other abstracts in this set, the evidence block supplies no numerical results and no assessment schedule.

Cerebrolysin and retracted preclinical reports

Several preclinical reports involving Cerebrolysin have been retracted, and the retraction notices are part of the supplied evidence. These cover a study of engineered silver, copper, or aluminium nanoparticles and blood-spinal cord barrier pathology [5], a study of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], a study of drug-loaded titanate nanospheres in a Parkinson's disease model [11], and a study of neurotrophic effects in the Mecp2^308/Y transgenic model of Rett syndrome [12]. These notices are cited so that readers can see which preclinical findings should not be relied on; they are not the subject of a section and no findings from the retracted work are reported here.

Reported timelines at a glance

What the timelines do and do not show

The shortest interval named in the supplied evidence is 24 hours, in a single case report of basilar artery occlusion [2]. The longest is 12 months, in a propensity-matched cohort abstract [8]. Between those, the evidence names a 10-day course in one aphasia case report [3] and a 6-to-24-hour treatment window in a trial protocol [1]. None of these are comparable to one another: they differ in design, population, route of administration, and whether an outcome was measured at all.

Two of the mechanistic items are in vitro or preclinical in nature. The endothelial permeability work was performed in cultured cerebral endothelial cells [4]. The retracted reports concern nanoparticle intoxication, transgenic mouse models, and a nanosphere delivery system [5][10][11][12]. No animal-only timeline is reported in the supplied evidence for any non-retracted study.

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing, administration, or medical guidance of any kind. Nothing on this page is a recommendation for or against use in a person, and the case reports and abstracts cited here describe individual clinical settings that cannot be generalised. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
• [2] Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — https://europepmc.org/article/PMC/PMC13474398
• [3] Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — https://europepmc.org/article/PMC/PMC13474394
• [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — https://europepmc.org/article/PMC/PMC13205112
• [5] Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles — https://europepmc.org/article/PMC/PMC13179879
• [6] ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — https://europepmc.org/article/PMC/PMC13146077
• [7] ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEUROREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — https://europepmc.org/article/PMC/PMC13145624
• [8] ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — https://europepmc.org/article/PMC/PMC13146562
• [9] Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — https://pubmed.ncbi.nlm.nih.gov/42666484/
• [10] Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice — https://pubmed.ncbi.nlm.nih.gov/42015030/
• [11] Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease — https://pubmed.ncbi.nlm.nih.gov/41920231/
• [12] Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome — https://pubmed.ncbi.nlm.nih.gov/41874695/